Drilldown: Medicines

Bisoprolol (1) · Hydroxychloroquine (1) · Nebivolol (1)

Bystolic (1) · Plaquenil; mostly prescribed generically (1) · Zebeta (1)

Beta Blocker (2) · Cardioselective (β1) (1) · Cardioselective (β1) + vasodilator (1) · [[:Category:Antimalarials|Antimalarial (4-aminoquinoline)]] (1) · [[:Category:DMARDs|DMARD]] (1) · [[:Category:Immunomodulators|Immunomodulator]] (1)

None (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1)

'"`UNIQ--vote-0000059D-QINU`"' (1) · '"`UNIQ--vote-00000636-QINU`"', '"`UNIQ--vote-00000637-QINU`"', '"`UNIQ--vote-00000638-QINU`"' (1) · '"`UNIQ--vote-000007E7-QINU`"', '"`UNIQ--vote-000007E8-QINU`"', '"`UNIQ--vote-000007E9-QINU`"', '"`UNIQ--vote-000007EA-QINU`"', '"`UNIQ--vote-000007EB-QINU`"' (1)

2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 200-400 mg PO daily; '''dose by actual body weight ≤5 mg/kg/d''' to reduce retinopathy risk (AAO 2016 guideline) (1) · 5 mg daily (1)

2.5, 5, 10, 20 mg tabs (1) · 200 mg tablets; 100 mg/5 mL suspension (1) · 5, 10 mg tabs (1)

20 mg/d (1) · 40 mg/d (1) · 400 mg/d typical maintenance; weight-adjusted ceiling per ophthalmology guidance (1)

Oral (3)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

24 h (2) · Weeks (long half-life) (1)

9–12 h (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~40 days (terminal; reflects extensive tissue distribution)'"`UNIQ--ref-000007EC-QINU`"' (1)

70-75% (oral)'"`UNIQ--ref-000007ED-QINU`"' (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~90% (low first-pass) (1)

Category C (2) · Long-considered safe in pregnancy for lupus and other rheumatologic indications; benefits typically outweigh.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

Rx-only in US (2) · [[USLegal:Prescription only|Rx-only]] in US (1)